UroGen Pharma (NASDAQ:URGN) Now Covered by Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research note released on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $31.00 target price on the stock.

Separately, D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $39.20.

UroGen Pharma Stock Down 5.9 %

Shares of NASDAQ URGN traded down $0.63 during trading hours on Wednesday, hitting $10.08. The company had a trading volume of 801,481 shares, compared to its average volume of 268,081. UroGen Pharma has a 1-year low of $9.78 and a 1-year high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm's 50 day moving average is $10.70 and its 200-day moving average is $12.16. The stock has a market capitalization of $236.38 million, a P/E ratio of -3.20 and a beta of 1.08.

Insider Activity at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company's stock, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors have recently made changes to their positions in URGN. KLP Kapitalforvaltning AS acquired a new stake in UroGen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC bought a new position in UroGen Pharma during the 4th quarter worth $67,000. China Universal Asset Management Co. Ltd. increased its position in UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock worth $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock worth $109,000 after buying an additional 5,890 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of UroGen Pharma in the fourth quarter valued at about $101,000. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.